摘要
目的比较酮替芬和孟鲁司特钠治疗支气管哮喘的临床疗效和长期症状控制情况。方法选择100例首次确诊为支气管哮喘的患者,均给予抗炎治疗和止咳、平喘等对症治疗。A组(n=50)在此基础上给予酮替芬片(0.5或者1.0mg),每日早晚各一次口服;B组(n=50)给予孟鲁司特钠(5或10mg),每晚一次口服。比较两组患者治疗2周后临床疗效,比较治疗2个月后症状控制情况。结果治疗2周后,A组治疗总有效率为84.0%(42/50),B组为96%(48/50),差异具有统计学意义(χ2=4.0,P<0.05);治疗2个月后,A组33例患者完全控制症状,B组43例,差异具有统计学意义(χ2=4.14,P<0.05)。结论酮替芬和孟鲁司特不良反应轻微,孟鲁司特的临床疗效和长期症状控制效果均优于酮替芬。
Objective To compare the effect of Ketotifen and montelukast in treating bronchial asthma.Methods Totally 100 patients who were newly diagnosed bronchial asthma were randomly divided into two groups,and group A have 50 cases,who were treated with Ketotifen（0.5 or 1.0mg）and use twice a day,AM and PM.Group B have 50 cases too,and were treated with montelukast（5 or 10mg）,qn,po.Compare the curative effect after 2 weeks.Results After 2 weeks treatment,the total effective rate of group A is 84.0%,and group B is 96.0%,and it has a significant difference between the two groups（χ2=4.0,P〈0.05）.The curative effect after 2 months treatment also has a significant difference between the two groups（χ2=4.14,P〈0.05）.Conclusion Both Ketotifen and montelukast are work for bronchial asthma,but montelukast is better than Ketotifen.
出处
《医药论坛杂志》
2013年第6期39-40,共2页
Journal of Medical Forum
